From preserved cells to living tissue.

It begins with governed biological material and the genomic and clinical data linked to it. Consent, provenance and auditability are decided here, and everything downstream inherits them.

A donor cell is returned to a pluripotent state, then expanded, characterised and cryobanked. A finite sample becomes a renewable one, and the line becomes the unit of work.

Bioreactor conditions, scaffolds, density and timing. This is the least glamorous stage and the one that decides whether results repeat, which is why most of the effort lives here.

The banked line becomes neural and hepatic tissue. Because both come from the same genome, the two pictures can be read together rather than separately.

Phenotyping, imaging and data integration, and from there a route toward therapy. Each step of that route has to be earned with evidence.

Reproducibility at cohort level, not at demonstration level. Same protocol, same result, different operator, different month.

Enough characterised lines that a neural and a hepatic result from one genome can be set against a population rather than against nothing.

A regulatory pathway walked deliberately, with GMP-grade process behind it, and evidence that survives review by people who are not us.